Lung microbiota dysbiosis and the implications of SARS-CoV-2 infection in pregnancy.
Henry C EzechukwuCornelius A DiyaIfunanya J EgohMayowa J AbiodunJohn-Ugwuanya A GraceGod'spower R OkohKayode T AduOyelola Abdulwasiu AdegboyePublished in: Therapeutic advances in infectious disease (2021)
There are a great number of beneficial commensal microorganisms constitutively colonizing the mucosal lining of the lungs. Alterations in the microbiota profile have been associated with several respiratory diseases such as pneumonia and allergies. Lung microbiota dysbiosis might play an important role in the pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as elicit other opportunistic infections associated with coronavirus disease 2019 (COVID-19). With its increasing prevalence and morbidity, SARS-CoV-2 infection in pregnant mothers is inevitable. Recent evidence shows that angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) act as an entry receptor and viral spike priming protein, respectively, for SARS-CoV-2 infection. These receptor proteins are highly expressed in the maternal-fetal interface, including the placental trophoblast, suggesting the possibility of maternal-fetal transmission. In this review, we discuss the role of lung microbiota dysbiosis in respiratory diseases, with an emphasis on COVID-19 and the possible implications of SARS-CoV-2 infection on pregnancy outcome and neonatal health.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- angiotensin converting enzyme
- pregnancy outcomes
- angiotensin ii
- healthcare
- preterm birth
- pregnant women
- public health
- risk factors
- binding protein
- birth weight
- physical activity
- respiratory tract
- mechanical ventilation
- amino acid
- extracorporeal membrane oxygenation
- protein protein
- gestational age